Orchid Pharma Ltd (NSE: ORCHPHARMA) and Supriya Lifescience Limited (NSE: SUPRIYA) are both listed in the Medicinal Chemicals and Botanical Products industry. Orchid Pharma has a market capitalisation of ₹5,074 Cr and Supriya Lifescience ₹6,746 Cr, as of 9 Nov 2026. Their P/E ratios are 510.4 and 32.3 respectively. Return on equity is 0.70% for Orchid Pharma and 19.06% for Supriya Lifescience. Over one year, Orchid Pharma's share price is up 14.8% and Supriya Lifescience's is down 19.2%.
| Metric | Orchid Pharma | Supriya Lifescience |
|---|---|---|
| NSE Symbol | ORCHPHARMA | SUPRIYA |
| BSE Code | 524372 | 543434 |
| Share Price | ₹884.00 | ₹628.10 |
| Market Cap | ₹5,074 Cr | ₹6,746 Cr |
| P/E Ratio | 510.4 | 32.3 |
| Return on Equity | 0.70% | 19.06% |
| Return on Assets | 0.12% | 13.46% |
| Dividend Yield | — | 0.12% |
| Beta (1Y) | 0.81 | 0.58 |
| 1-Year Price Change | +14.8% | -19.2% |
| 3-Month Price Change | -18.1% | -31.9% |
| 52-Week Range | ₹480.00 – ₹1,143.50 | ₹545.50 – ₹1,085.00 |
| Latest Quarter | Q1 FY27 | Q2 FY27 |
| Quarterly Revenue | ₹304 Cr | ₹206 Cr |
| Quarterly Net Profit | ₹3 Cr | ₹29 Cr |
| Net Margin | 1.1% | 14.2% |
| EPS (Basic, Quarter) | ₹0.54 | ₹3.63 |
| Results Basis | consolidated | standalone |
| Headquarters | Chennai, Tamil Nadu | Mumbai, Maharashtra |
The figures sit side by side and are not ranked. Quarterly figures are in ₹ crore, parsed from each company's exchange filing (XBRL); the two companies' latest quarters can differ.
Orchid Pharma Limited, a pharmaceutical company, engages in the development, manufacture, and marketing of active pharmaceutical ingredients, bulk actives, finished dosage formulations, and nutraceuticals in India. Its active pharmaceutical ingredients product portfolio includes oral cephalosporins, injectable cephalosporins; human and veterinary products; and antibiotics, including betalactam, macrolide, fluoroquinolone, and imidazole. The company also exports its products to approximately 40 countries internationally. The company was formerly known as Orchid Chemicals & Pharmaceuticals Limit…
Supriya Lifescience Limited engages in the research and development, manufacture, and sale of bulk drugs and pharmaceutical chemicals worldwide. The company offers active pharmaceuticals ingredients in antihistamine, anti-allergic, anti-asthmatic, decongestant, analgesic/anti-pyretic/anesthetic, anti–hypertensive, vitamins, anti-malarial, and anti-gout areas. It also provides oncology, veterinary, and general category products. In addition, the company offers GelHeal, a wound care solution; and Quickblue, an oral cancer detection kit. Further, it is developing drugs in the areas of anti-depres…
Supriya Lifescience has a market capitalisation of ₹6,746 Cr, against ₹5,074 Cr for Orchid Pharma as of 9 Nov 2026, about 1.3 times the size by market cap.
Orchid Pharma has a P/E of 510.4 and Supriya Lifescience a P/E of 32.3 as of 9 Nov 2026.
Orchid Pharma has a return on equity of 0.70% and Supriya Lifescience 19.06%.
Orchid Pharma's share price is up 14.8% over one year and Supriya Lifescience's is down 19.2%.
Orchid Pharma reported revenue of ₹304 Cr and net profit of ₹3 Cr for Q1 FY27. Supriya Lifescience reported revenue of ₹206 Cr and net profit of ₹29 Cr for Q2 FY27. Figures are parsed from each company's exchange filing.
Both are classified under Pharmaceuticals > Biotechnology and Life Sciences > Medicinal Chemicals and Botanical Products on FinBizNet.
No. The page lays the two companies' published figures side by side and draws no conclusion from them. It is descriptive market data, not investment advice.
Data as of 9 Nov 2026. Descriptive market data only — not investment advice.